Introduction

Atherothrombosis is the main cause of death worldwide. Traditional cardiovascular risk factors (CVRF), such as diabetes, smoking, dyslipidemia, hypertension, explain 70 to 75% of cardiovascular events suffered by patients. However, a significant part of these events remains unexplained given that 25 to 30% of people without any evident cause can present an atherosclerotic cardiovascular event (CVE), whereas not all high-risk subjects (according to traditional CVFR) experience such an event.¹

Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a potential new risk factor of cardiovascular diseases.² This condition results from the acquisition by a hematopoietic stem cell of somatic mutations in leukemia-driver genes, leading to clonal expansion of a population of hematopoietic cells without any clinical or biological sign of hematological malignancy. The definition of CHIP proposed to date, requires the detection of the mutation at a variant allele frequency (VAF) of more than 2%, representing a proportion of mutated cells of more than 4%.³ The most commonly mutated genes in CHIP are DNA Methyltransferase 3A (DNMT3A) and Ten Eleven Translocation 2 (TET2). In 2014, Jaiswal et al showed that CHIP was associated with a decreased survival mainly because of an increased atherothrombotic mortality. In particular, they observed a 2.0 fold-increased risk of myocardial infarction (MI) and a 2.6-fold increased risk of ischemic stroke.² In 2017, these data were confirmed, showing a 1.9-fold increased risk of coronary heart disease in the presence of CHIP, independently of traditional CVRF.⁴ At the same time, a causative role of CHIP in inducing atherosclerosis has been demonstrated in animal models through the induction of a proinflammatory state.^4,5 More recently, Kessler et al showed in 454 803 subjects from the UK Biobank that the association of CHIP with atherothrombotic events was restricted to high VAF clones (ie ≥10%) with a much lower risk than initially demonstrated (HR=1.11).⁶ But even with these criteria, no association between CHIP and atherothrombotic events was found in a validation cohort of 173 585 subjects,⁶ which has also been suggested in another work studying several hundred thousand subjects.⁷ Thus, the impact of CHIP on atherothrombosis in humans is not totally evident, possibly because of the existence of yet unidentified modulating factors that could potentiate or counteract the effect of CHIP. For example, the p.Asp358Ala variant of the IL6 receptor gene has been shown to decrease the atherothrombotic risk associated with CHIP.^8,9 However, the impact other genetic variants on the cardiovascular risk associated with CHIP remains unknown.

Gain or loss of chromosomes in hematopoietic cells appears to be as frequent as the acquisition of somatic mutations during aging.¹⁰ In particular, mosaic loss of chromosome Y (mLOY) has been shown to be frequent in male subjects without evidence of hematological malignancy.^11,12 mLOY was associated with cardiovascular diseases,^13,14 and can be detected in a rather high proportion of subjects with CHIP.^15,16 Finally, while TET2 mutations promote inflammation and atherosclerosis in mouse models,⁴ mLOY was shown to switch macrophages from a pro-inflammatory to a pro-fibrotic phenotype.¹⁴ Thus, because of their opposite effect on macrophages phenotype, mLOY could balance the effect of CHIP regarding the induction of inflammation and thus decrease the development of atherosclerosis and the resulting atherothrombotic risk. We thus hypothesized that mLOY could modulate the effect of CHIP in inducing inflammation, atherosclerosis and triggering atherothrombotic events.

In this study, we used sensitive technics to determine the prevalence of both CHIP and mLOY in 2 cohorts of subjects. We sought to determine whether CHIP and mLOY significantly increase the cardiovascular risk separately. We also searched to determine in humans whether mLOY could impact the effect of CHIP on inflammation, atherosclerosis burden or atherothrombotic risk.

Methods

Patients

For this study, we recruited 446 patients: 149 with a first MI and 297 without a MI or other CVE at inclusion. The 149 subjects with a MI were enrolled in the CHAth study between March 2019 and October 2021 (MI(+) subjects). The main eligibility criterion was suffering from a first MI of atherosclerosis origin after 75 years of age without evidence of hematological malignancy (Supplementary Figure S1). They were included between 4+/-2 months after the acute event, in order to assess their basal inflammatory state. In the presence of any clinical sign or factor associated with inflammation, the appointment was reported in order not to skew biological and genetic data. Additionally, we ensured that the subjects had not been vaccinated against SARS-Cov2 within 15 days of enrollment. The study was approved by the institutional review board (IRDCB 2019-A02902-05), and registered (https://www.clinicaltrials.gov: NCT04581057). All participants gave written informed consent before inclusion in the study. Eligibility and exclusion criteria are more detailed in the Supplementary Methods.

As a control cohort, we selected subjects without any history of CVE at inclusion in the 3-city (3C) study cohort (MI(-) subjects, Supplementary Figure S1).¹⁷ The 3C study is a prospective study that enrolled 9294 subjects of 65 years or more who were selected upon electoral lists. These subjects were followed for several years (up to 12 years) to detect the development of dementia from a vascular origin. As such, they benefitted from a stringent cardiovascular follow-up, with adjudication of all cardiovascular events (in particular occurrence of MI). Among these subjects, we selected the 297 subjects who did not present any CVE before inclusion. Seventy-nine of them presented a MI during follow-up. The remaining 218 subjects had no atherothrombotic event during follow up, and were matched on age, sex and CVRF with those who had a MI during follow up (Supplementary Figure S1).

Clinical and biological parameters measured at inclusion

In MI(+) subjects, a routine cardiovascular evaluation was performed at inclusion (between 2 and 7 month after MI occurrence). Subjects were asked about presence of dyspnea or angina, evaluated with NYHA and CCS scales. Information was obtained from medical records about a potential recurrence of a cardiovascular event since the index event (new MI, coronary revascularization, stroke, hospitalization for acute heart failure). Traditional cardiovascular risk factors were noted. Routine biological analyses comprising blood count, high-sensitive CRP (hsCRP), lipid profile, HbA1c were performed in the laboratory of the university hospital of Bordeaux on fresh samples.

For MI(-) subjects, data available at inclusion included hsCRP level, lipid profile and traditional CVRF. No blood count was available but none of the subjects developed cancer (including hematological malignancy) during follow-up suggesting that detectable somatic mutations were indicative of CHIP and not hematological malignancy.

Measurement of atherosclerosis burden

For MI(+) subjects, a transthoracic echocardiography was performed at inclusion by trained cardiologists and ejection fraction calculated. Supra-aortic trunks ultrasonography with 3D-measurement of atherosclerotic volume was performed by trained physicians, using a Philips iU22 probe equipped with a linear-3D volume convertor VL13-5 (Philips). Images were analyzed using the Vascular Plaque Quantification software on the QLAB 10.2 system (Philips). Carotid stenosis quantification was done with NASCET criteria. Functional ischemic testing was performed at the clinicians’ discretion. For MI(-) subjects, atherosclerosis burden was assessed at the inclusion by ultrasound echography recording detection of atherosclerotic plaques, atherosclerotic plaque numbers and intima-media thickness.

Follow up of subjects

For MI(+) subjects, the follow-up was conducted with a standardized questionnaire previously validated in clinical trials.¹⁸ Recurrence of MI as well as any significant cardiovascular event (cardiovascular death, acute coronary syndrome, stroke or transient ischemic attack, congestive heart failure, secondary coronary revascularization, or peripheral vascular surgery) occurring between the initial event and the year after inclusion in the study were recorded. All medical records of participants who died, or who reported on the questionnaire that they had experienced cardiovascular symptoms between baseline and follow-up evaluations, were reviewed by one of the investigators, and the patient practitioners were contacted. For MI(-) subjects, a follow up was performed for up to 12 years. All cardiovascular events were recorded (including MI) with adjudication upon medical records by an expert committee (Figure 1).

Figure 1:

Search for somatic mutations and mosaic loss of chromosome Y

For both MI(+) and MI(-) subjects, DNA was extracted from total leukocytes obtained at inclusion. The search for somatic mutations was carried out by the Laboratory of Hematology of the University Hospital of Bordeaux using the Next Generation Sequencing (NGS) panel designed for the diagnosis and follow-up of myeloid hematological malignancies. The genes tested are detailed in Supplementary Table S1.

Briefly, target sequences were captured using the SureSelect technology (Agilent). Sequencing was performed on a NextSeq 550Dx Instrument (Illumina technology) and analyzed using an in-house bioinformatics pipeline (see Supplementary Methods for more details). Variants interpretation was performed independently by two biologists according to criteria previously described¹⁹ and reported in Supplementary Table S2. According to the definition of CHIP, only mutations with a VAF ≥ 2% were retained.

The search of mLOY was performed thanks to an in-house droplet digital PCR technic using the following primers and probes:

• - Primer-amel-Fwd: 5’-CCCCTGGGCACTGTAAAGAAT

• - Primer-amel-Rev: 5’-CCAAGCATCAGAGCTTAAACTG

• - Probe-amelX: 5’-HEX-CCAAATAAAGTGGTTTCTCAAGT-BHQ

• - Probe-amelY: 5’-FAM-CTTGAGAAACATCTGGGATAAAG-BHQ.

Briefly, 75 ng of DNA was mixed with ddPCR supermix for Probes (no dUTP, Biorad), primers (0.9µM each) and probes (0.25µM each). The emulsion was prepared with the QX-100 (Biorad). The amplification program was as follows: 10-minutes denaturation at 95°C, followed by 40 cycles of 30 seconds at 94°C, 1 minute at 55°C, and inactivation of 10 minutes at 98°C. The number of droplets positive for amelX and amelY was determined on the QX-200 droplet reader (Biorad) using the Quantasoft software version 1.5 (Biorad). At least 10,000 droplets were analyzed in each well. A cut off of 9% of cells with mLOY defined the detection of a mLOY based on the study of 30 men of less than 40 years who had a normal karyotype as assessed by conventional cytogenetic study.

Statistical analyses

Univariate association analyses were conducted using Fisher exact or Chi-square test statistics for categorical variables. Analysis of variance was used for quantitative variables. Multivariate association analyses were performed using logistic or linear regression models as appropriate. Analyses were adjusted for age and sex (CHIP) or for age only (mLOY). We used raw values for all quantitative variables as they presented a normal distribution, except for CRP levels for which we analyzed log(CRP). Log-rank test statistics were employed to assess the association of clinical/biological variables with the incidence of future cardiovascular events.

All analyses were conducted using either the RStudio software (Posit team (2023). RStudio: Integrated Development Environment for R. Posit Software, PBC, Boston, MA. URL http://www.posit.co/.) or the PRISM software (GraphPad Prism version 9.5.1).

Results

Patient’s characteristics

In this study, we aimed to decipher whether mLOY could alter the effect of CHIP in inducing a chronic inflammation that would favor the development of atherosclerosis and the incidence of atherothrombotic events. To answer this question, we analyzed 446 subjects from 2 prospective studies, 149 who presented a MI at inclusion and 297 who did not present any CVE before inclusion. The general characteristics of the 446 combined subjects are detailed in Table 1. Briefly, the median age was 76.4 years and 257 (57.6%) were males. Forty percent of them presented more than 2 CVRF. MI(+) subjects were older (due to the inclusion criteria), more frequently men, and presented a lower cardiovascular risk than MI(-) subjects (due to the initiation of treatment between the initial event and the inclusion).

Table 1:

CHIP and mLOY are detected as frequently in MI(+) and MI(-) subjects

Among the 446 subjects, at least one mutation with a VAF≥2% was detected in 201 persons (45.1%), defining CHIP(+) subjects (Table 1, Figure 1A). As previously described, DNMT3A and TET2 were the 2 most frequently mutated genes. The other mutated genes were those previously described in CHIP (Figure 1B)^2,4,16 and the median VAF was 2% (Figure 1C). The mutational profile of CHIP(+) subjects is available in the Supplementary Tables S3 and S4 while the characteristics of CHIP(+) compared with CHIP(-) subjects are detailed in the Supplementary Tables S5 and S6. In this study, we considered subjects without any detectable mutation or with only mutations with a VAF below 2% as non-CHIP carriers (CHIP(-) subjects).

A mLOY was present in 83 (37.7%) male subjects (mLOY(+) subjects, Table 1, Figure 1A). The clinico-biological characteristics of mLOY(+) subjects compared with mLOY(-) subjects are detailed in the Supplementary Tables S5 and S6. The median proportion of cells with mLOY was 18% [12%;32%]. There was no significant association between CHIP and mLOY since 39 CHIP(+) subjects (39.8%) also carried a mLOY compared with 44 CHIP(-) subjects (36.1%, p=0.579). Finally, as previously demonstrated, CHIP(+) subjects were significantly older than CHIP(-) subjects (Supplementary Tables S5 and S6). We also observed an increasing prevalence of both CHIP and mLOY with age (Figure 1D).

We observed a similar frequency of CHIP and mLOY in MI(+) and MI(-) subjects (Figure 1A, Table 1). Besides, the association of CHIP with mLOY was as frequent in MI(+) and MI(-) subjects (22.7% and 13.8%, p=0.797). Of note, MI(+) and MI(-) subjects presented similar proportions of mutated genes (Figure 1B) and VAF (Supplementary Figure 2). Similar results were also observed when considering CHIP associated with important clones (i.e. VAF≥5%, Table 1). or when analyzing only DNMT3A and TET2 mutations (data not shown).

Altogether, these results suggest that CHIP and mLOY are very frequent but not associated with the existence of a history of MI, even when mLOY is associated with CHIP.

Neither CHIP, mLOY, nor their combination highly increase basal inflammation or atherosclerotic burden

It was demonstrated that TET2 mutations were associated with the induction of a pro-inflammatory phenotype of macrophages.⁵ On the contrary, mLOY was shown to decrease the inflammatory phenotype of macrophages.¹⁴ Therefore, we searched to determine whether mLOY could counter the inflammatory state that would be associated with CHIP. In the total cohort, CHIP(+) and CHIP(-) subjects presented similar levels of hsCRP, as did mLOY(+) and mLOY(-) subjects (Table 2). Similarly, hsCRP levels were not different in CHIP(-)/mLOY(-), CHIP(+)/mLOY(-), CHIP(-)/mLOY(+) and CHIP(+)/mLOY(+) subjects. The impact of CHIP and mLOY on hsCRP levels, either alone or in combination, was comparable in MI(+) or MI(-) subjects (Table 2). This was also true when restricting the analysis to DNMT3A and TET2 mutated CHIP(+) subjects (Supplementary Table S7). Finally, subjects with important CHIP or mLOY clones did not present higher levels of hsCRP (Supplementary Table S8).

Table 2:

Very few data are available about atheroma burden associated with CHIP and/or mLOY in humans. Moreover, the modulation of the atherogenic effect of CHIP by mLOY remains unexplored. We thus asked whether CHIP alone or in association with mLOY was associated with an increased atherosclerotic burden. In MI(+) subjects we observed a similar proportion of multitroncular coronary lesions and carotid stenosis >50% in CHIP(+) and CHIP(-) subjects (Table 3). The global atheroma volume was explored by 3D ultrasound in 34 MI(+) patients, without difference between CHIP(+) and CHIP(-) subjects. Similar results were obtained when analyzing only CHIP(+) subjects carrying TET2 and/or DNMT3A mutations (Supplementary Table S7), when comparing mLOY(+) and mLOY(-) subjects (Table 3), or when analyzing the association of CHIP with mLOY (Supplementary Table S9). Concordantly, in MI(-) subjects, all available atherosclerosis markers were similar between CHIP(+) and CHIP(-), as well as between mLOY(+) and mLOY(-) subjects (Table 3). This was also true when analyzing the effect of the different combinations of CHIP and mLOY (Supplementary Table S9). Once again, all these results were confirmed in subjects with a VAF ≥5% for CHIP or a mLOY≥50% (Supplementary Table S8).

Table 3:

Altogether, our results suggest that both in the context of a recent MI and in healthy individuals, CHIP were not associated with a systemic inflammation or an increased atherosclerotic burden. mLOY do not modulate inflammatory parameters or atherosclerosis, even in the presence of CHIP.

Neither CHIP, mLOY, nor their combination highly impact the incidence of MI

To decipher whether mLOY could impact the atherothrombotic risk associated with CHIP, we analyzed the incidence of MI during the follow-up of MI(-) subjects. Seventy-nine subjects developed a MI after inclusion in the study with a median delay of 5.00 years. Subjects with MI during follow-up did not differ significantly from those without MI in terms of demography or cardiovascular risk (Supplementary Table S10). CHIP, mLOY and their association were not significantly associated with an increased incidence of MI (Figure 2A-B, Supplementary Table S11). Concordantly, we did not observe any difference in the prevalence of CHIP, mLOY or their association between MI(-) subjects who suffered from a MI during follow up and those who did not (Supplementary Table S10). This was also the case when restricting the analysis to CHIP with a VAF ≥5%, a proportion of cells with mLOY ≥50% or to CHIP associated with DNMT3A or TET2 mutations (Supplementary Figure S3A-S3B, Supplementary Table S10). These results suggest that the atherothrombotic risk associated with CHIP is moderate, and is not modulated by its association with mLOY. Moreover, neither CHIP, mLOY nor their combination were significantly associated with atherothrombotic recurrence (Supplementary Table S11).

Figure 2:

CHIP in the absence of mLOY may accelerate the occurrence of MI

In order to search for a combined effect of CHIP with mLOY on the risk of incidence of MI, we finally focused our analysis on MI(-) male subjects. In this population, we observed that MI occurred earlier in CHIP(+) subjects, with a significant increased 5-year incidence of MI (log-rank test, p=0.0142, Figure 2C). Such an effect was not observed in MI(-) female subjects (log-rank test, p=0.9402, Supplementary Figure S3C). Interestingly, this effect was more pronounced in CHIP(+)/mLOY(-) subjects who presented a significantly higher 5-year incidence of MI (log-rank test, p=0.0104, Figure 2D) and a significantly lower median time to MI compared with other subjects (Kruskall-Wallis test, p=0.007). Altogether, our results suggest that CHIP do not increase the risk of MI, but may accelerate its incidence, particularly in the absence of mLOY.

Discussion

Clonal hematopoiesis of indeterminate potential (CHIP) has previously been implicated in decreased overall survival, primarily due to its association with an increased incidence of cardiovascular diseases such as coronary artery disease (CAD) and stroke.^2,4 Experimental models have suggested that this association may arise from the pro-inflammatory phenotype of mutated monocytes/macrophages, contributing to the development of atherosclerotic plaques.^4,5 However, recent findings in the literature have presented a complex and sometimes contradictory picture. Studies have reported varying results regarding the relationship between CHIP, inflammation markers, and atherothrombotic events, challenging the initial notion of a high atherothrombotic risk associated with CHIP.^6,7,9,20,21 Moreover, there has been a scarcity of evidence linking CHIP to an increased burden of atherosclerosis in human subjects.^4,22 Additionally, limited data are available on the potential impact of chromosomal abnormalities, particularly mosaic loss of the Y chromosome (mLOY), on atherothrombosis in individuals with CHIP. In this study, we sought to investigate whether mLOY could modulate the effects of CHIP concerning systemic inflammation, atherosclerotic burden, and the risk of atherothrombotic events. To achieve this, we employed sensitive techniques, including targeted high-throughput sequencing and digital PCR, to analyze samples from two cohorts of meticulously phenotyped subjects.

In contrast to many previous studies, we conducted a comprehensive analysis involving two distinct cohorts. The “cases” were individuals recruited from the CHAth study within 2 to 7 months following their first myocardial infarction (MI) after the age of 75. We also established a “control cohort” comprising 297 subjects from the 3-city cohort, none of whom had experienced CVE before inclusion. This allowed us to assess the effects of CHIP and mLOY on inflammation and atherosclerosis independently of pre-existing cardiovascular disease.

Our analysis revealed a remarkably high frequency of CHIP, with an estimated prevalence of 45% among our 446 subjects, with a median age of 76.4 years. This prevalence exceeded initial reports of 15-20% determined by whole exome sequencing (WES) in individuals aged 70-80,^2,23 likely attributable to the enhanced sensitivity of our sequencing technique. Importantly, our estimated prevalence aligns with studies employing similarly sensitive high-throughput sequencing techniques.^24–27 Furthermore, our approach allowed us to reliably detect mutations with a variant allele frequency (VAF) as low as 1%. We chose to define subjects with detectable mutations at a VAF of 1% as CHIP(-), aligning with the WHO definition of CHIP.²⁸ Notably, all our analyses also yielded identical results when comparing CHIP(+) patients to subjects without detectable mutations.

A recent study by Mas-Peiro et al. demonstrated an association between mLOY and increased post-transcatheter aortic valve replacement (TAVR) mortality.²⁹ In their investigation, a mLOY ratio threshold of 17% was deemed the most relevant for discriminating patients’ mortality risk. In our study, we employed a mLOY threshold of 9% to identify mLOY, a value determined through DNA samples from patients for whom the absence of mLOY had been definitively established through conventional cytogenetic analysis and an age below 40 years. Using this threshold, we frequently detected mLOY in male subjects within our cohort, with an estimated prevalence of 37.7% among 220 subjects. This prevalence surpasses that reported by Forsberg et al ³⁰ but aligns with recent findings from studies employing sensitive techniques.¹⁶

Surprisingly, our cohort did not reveal any significant association between the presence of CHIP and the detection of mLOY. This contrasts with the results of two recent studies,^15,16 possibly explained by the heightened sensitivity of our methodology in reliably detecting both somatic mutations and mLOY, which may exist in very small proportions of blood cells.

Mouse models of CHIP have recently suggested that somatic mutations are linked to a pro-inflammatory phenotype of mutated monocytes/macrophages, an observation supported by human samples using single-cell RNA sequencing.³¹ However, contradictory results have emerged when examining plasmatic markers of inflammation. Studies, including ours, have not consistently identified a significant increase in plasma hsCRP or proinflammatory cytokines in CHIP carriers,^25,32 whereas others have reported such associations.^20,21 Importantly, our study did not observe any significant association between the detection of CHIP(+/-)mLOY and plasma levels of IL1ß and IL6 in MI(+) subjects, suggesting that CHIP’s association with increased systemic inflammation may depend on specific stimulating factors. Notably, recent studies have reported elevated levels of plasma inflammatory markers in CHIP carriers during atherothrombotic events, such as MI or stroke,^33–35 indicating that CHIP may amplify systemic inflammation under specific conditions, but not necessarily in a basal state, as in our study.

To date, only a limited number of studies have successfully linked the presence of CHIP to an increased atherosclerotic burden. While Jaiswal et al. reported a higher calcic score in subjects with CHIP⁴, and Zekavat et al. suggested an increased atherosclerosis,²² these evaluations relied on self-reported atheroma and indirect parameters. Our study stands as the first to utilize direct markers of atherosclerosis, including global atheroma volume, in CHIP(+) subjects within the context of coronary artery disease. Strikingly, we did not detect a clear increase in atherosclerosis among CHIP or mLOY carriers, either individually or in combination. Conversely, increased atherosclerotic burden associated with CHIP has been observed in patients with stroke.³⁶

Our cohort comprising 449 subjects was unable to establish a direct association between CHIP, either alone or in conjunction with mLOY, and coronary heart disease. These results align with previous studies that reported either no difference in CHIP prevalence between individuals with MI and those without,²¹ or no significant association between CHIP and incident de novo or recurrent atherothrombotic events.^7,34,37 Recently, Kessler et al. proposed that the increased risk of atherothrombotic events might be limited to CHIP with a VAF of 10% or higher.⁶ However, even when considering this criterion, the association was not validated in a cohort of 173,585 subjects. Notably, at the time of our study’s initiation, the literature suggested an increased MI risk associated with CHIP, with a hazard ratio of 1.9-2.0. Based on this data, a cohort of 112 cases would have been sufficient to demonstrate a more frequent detection of CHIP in MI(+) patients compared to MI(-) subjects with a power of 0.90. This underscores the formidable challenges of identifying associations with low effect sizes, necessitating cohorts comprising hundreds of thousands of subjects to achieve statistical significance. Regarding specific mutations in DNMT3A, TET2 or other genes, our study did not reveal differing effects on inflammation, atherosclerosis, or MI incidence. Collectively, these findings suggest that any atherothrombotic risk associated with CHIP is limited in scope.

In conclusion, our study does not provide substantive evidence supporting a significant association between CHIP and substantial systemic inflammation, a pronounced increase in atherosclerotic burden, or a markedly elevated atherothrombotic risk. Additionally, mLOY did not appear to significantly modulate inflammation or atherosclerosis in the presence of CHIP. However, our data suggests that CHIP might expedite the onset of MI, particularly in the absence of mLOY. These findings warrant further investigation in larger subject cohorts.

While our study bears some limitations, including a relatively modest sample size of 449 subjects and recruitment of subjects within 2 to 7 months post-MI, it possesses strengths. Notably, we employed highly sensitive techniques for the reliable detection of both CHIP and mLOY, surpassing the capabilities of large cohort studies relying on whole exome sequencing and SNP arrays. Furthermore, we meticulously assessed atherosclerotic burden using sensitive parameters and conducted a thorough evaluation of two cohorts—one comprising MI(+) subjects and the other MI(-) subjects—with precise cardiovascular phenotyping at inclusion and rigorous follow-up, including direct evaluation and adjudication of all CVE.

In summary, our findings provide a nuanced perspective on the relationship between CHIP, mLOY, and cardiovascular outcomes, highlighting the need for larger, more comprehensive studies to elucidate potential associations further.

Data Availability

All data produced in the present work are contained in the manuscript.

Acknowledgements

The authors would like to thank the CRB-K of the University Hospital of Bordeaux for processing of the samples and Coralie Foucault and the Agilent Society for their partnership in supplying NGS reactive. We also thank Marina Migeon, Joël Decombe and Candice Falourd for their technical help, as well as Christel Duprat and Matthieu Meilhan for operational organization of the project.

Authorship

TC, OM and CJ designed the study. SF, YP, TC, AG and JB enrolled the subjects in the CHAth study and performed all cardiovascular evaluation. AS, CT and SD set up the 3 City Study Cohort. AB, SM, OM analyzed the NGS data. MD and DAT realized the statistical analysis. SF, SM, MD, DAT, CJ, OM and TC wrote the paper. All authors read and agreed to the final version of the manuscript.

Author approval

All authors have seen and approved the manuscript.

Disclosures

The authors report no conflict of interest.

Sources of Funding

This study was supported by the Fondation Cœur & Recherche (the Société Française de Cardiologie), the Fédération Française de Cardiologie, ERA-CVD (« CHEMICAL » consortium, JTC 2019) and the Fondation Université de Bordeaux. The laboratory of Hematology of the University Hospital of Bordeaux benefitted of a convention with the Nouvelle Aquitaine Region (2018-1R30113-8473520) for the acquisition of the Nextseq 550Dx sequencer used in this study.

Registration

URL: https://clinicaltrials.gov; Unique identifier: NCT04581057.